GetTopicDetailResponse(id=a0cf12350124, topicName=利厄替尼, introduction=, content=非小細(xì)胞肺癌 利厄替尼, image=null, comments=0, allHits=342, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Mon Jan 20 11:14:27 CST 2025, time=2025-01-20, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=500708, tagList=[TagDto(tagId=500708, tagName=利厄替尼)], ipAttribution=威斯康星, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2273467, encodeId=643822e346723, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=a0cf12350124' target=_blank style='color:#2F92EE;'>#利厄替尼#</a>, objectTitle=Lancet Respir Med：石遠(yuǎn)凱教授團(tuán)隊(duì)揭示利厄替尼作為一線(xiàn)治療EGFR敏感突變晚期非小細(xì)胞肺癌，PFS達(dá)20.7個(gè)月，腦轉(zhuǎn)移患者獲益明確, objectType=article, longId=886896, objectId=5a27886896b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=5a27886896b9, replyNumber=0, likeNumber=34, createdTime=2025-07-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5a27886896b9, moduleTitle=Lancet Respir Med：石遠(yuǎn)凱教授團(tuán)隊(duì)揭示利厄替尼作為一線(xiàn)治療EGFR敏感突變晚期非小細(xì)胞肺癌，PFS達(dá)20.7個(gè)月，腦轉(zhuǎn)移患者獲益明確, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5a27886896b9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2248854, encodeId=92d122488546d, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細(xì)胞肺癌#</a> <a href='/topic/show?id=a0cf12350124' target=_blank style='color:#2F92EE;'>#利厄替尼#</a>, objectTitle=第三代EGFR-TKI利厄替尼（奧壹新）國(guó)內(nèi)獲批上市！用于經(jīng)治EGFR T790M突變陽(yáng)性肺癌！ORR達(dá)68.8%, objectType=article, longId=860285, objectId=cc0f8602858e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301015/1697393515986_4754896.jpeg, objectUrl=/article/show_article.do?id=cc0f8602858e, replyNumber=0, likeNumber=30, createdTime=2025-01-20, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=cc0f8602858e, moduleTitle=第三代EGFR-TKI利厄替尼（奧壹新）國(guó)內(nèi)獲批上市！用于經(jīng)治EGFR T790M突變陽(yáng)性肺癌！ORR達(dá)68.8%, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cc0f8602858e)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-01-20發(fā)表于威斯康星
